12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vargatef nintedanib: Preliminary Phase I/II data

Preliminary data from 28 patients with advanced HCC in the dose-escalation Phase I portion of an open-label, European Phase I/II trial showed that the MTD of nintedanib was 200 mg given twice daily. The most common adverse events were gastrointestinal disorders. The Phase...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >